drugset / Trial / NCT00846547

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

NCT00846547

Phase 2 Completed 32 enrolled Seaside Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability. We hypothesize that STX209 will be safe and well-tolerated.

Timeline

Start
2009-02
Primary completion
2010-06
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Arbaclofen Small molecule 1 mg Oral
Subject Arbaclofen Small molecule 10 mg Oral